{"id":7187,"date":"2018-11-17T17:17:05","date_gmt":"2018-11-18T01:17:05","guid":{"rendered":"https:\/\/www.bluerocktx.com\/?p=7187"},"modified":"2023-06-26T14:36:52","modified_gmt":"2023-06-26T18:36:52","slug":"bluerock-therapeutics-to-participate-at-upcoming-conferences","status":"publish","type":"post","link":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-to-participate-at-upcoming-conferences\/","title":{"rendered":"BlueRock Therapeutics to Participate at Upcoming Conferences"},"content":{"rendered":"
CAMBRIDGE, Mass., Nov. 7, 2018<\/strong>\u00a0\u2013 BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows:<\/p>\n American Heart Association Scientific Sessions 2018<\/strong><\/p>\n Session<\/strong>: Stem Cells and Their Derivatives as Therapeutics NY\/NJ CEO<\/strong><\/p>\n Presentation<\/strong>: Spotlight: Building a Biotech About BlueRock Therapeutics<\/strong><\/p>\n BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock\u2019s Cell+Gene platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock\u2019s cell differentiation technology recapitulates the cell\u2019s developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock\u2019s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com<\/a>.<\/p>\n ###<\/p>\n Media Contacts:<\/strong> CAMBRIDGE, Mass., Nov. 7, 2018\u00a0\u2013 BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows: American Heart […]<\/p>\n","protected":false},"author":2,"featured_media":7708,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[45],"tags":[55],"acf":[],"yoast_head":"\n
\nPresentation<\/strong>: Venture Capital and Industry Perspective on Cell Therapy
\nDate<\/strong>: Monday, Nov. 12, 2018 at 8:00 a.m. EST
\nLocation<\/strong>: McCormick Place, S102bc, Chicago
\nFor more information, please visit<\/strong>: https:\/\/professional.heart.org\/professional\/EducationMeetings\/MeetingsLiveCME\/ScientificSessions\/UCM_316<\/a>
\n900_Scientific-Sessions.jsp<\/p>\n
\nDate<\/strong>: Wednesday, Nov. 14, 2018 at 3:00 p.m. EST
\nLocation<\/strong>: Apella by Alexandria Center, New York
\nPanel Presentation<\/strong>: Early Stage Biotech: Strategies for Survival
\nDate<\/strong>: Wednesday, Nov. 14, 2018 at 3:15 p.m. EST
\nLocation<\/strong>: Apella by Alexandria Center, New York
\nFor more information, please visit<\/strong>: https:\/\/lifesciences.knect365.com\/ny-nj-ceo\/<\/a><\/p>\n
\nDavid Schull or Maggie Beller
\nRusso Partners, LLC
\n(646) 942-5631
\nMaggie.beller@russopartnersllc.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"